Study Evaluating 2 Dosing Regimens Of TRU-015 In Rheumatoid Arthritis

Stopped early · Phase 2 · Has a placebo group

Conditions studied: Arthritis, Rheumatoid

In brief

This study will evaluate the efficacy and safety of two dosing regimens of a compound known as TRU-015 in combination with methotrexate (MTX) in patients with active rheumatoid arthritis.

Key facts

Study ID

NCT00634933

Run by

Pfizer

People needed

222

Starts

2008-03-01

Expected to finish

2012-10-01

Last updated by the study team

2013-03-11

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Clinical diagnosis of active seropositive rheumatoid arthritis on a stable dose of methotrexate (7.5-25 mg weekly) for at least 12 weeks with or without a history of anti-TNF use.

You may not qualify if…

• Any prior use of rituximab or other B cell depleting agents.
• Any significant health problem other than rheumatoid arthritis
• Clinically significant laboratory abnormalities

Where it is running

• Pfizer Investigational Site — Paradise Valley, Arizona, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Los Angeles, California, United States
• Pfizer Investigational Site — Santa Maria, California, United States
• Pfizer Investigational Site — Santa Monica, California, United States
• Pfizer Investigational Site — Daytona Beach, Florida, United States
• Pfizer Investigational Site — Ocala, Florida, United States
• Pfizer Investigational Site — Palm Harbor, Florida, United States
• Pfizer Investigational Site — Chicago, Illinois, United States
• Pfizer Investigational Site — Springfield, Illinois, United States
• Pfizer Investigational Site — Worcester, Massachusetts, United States
• Pfizer Investigational Site — Worcester, Massachusetts, United States
• Pfizer Investigational Site — Grande Rapids, Michigan, United States
• Pfizer Investigational Site — Flowood, Mississippi, United States
• Pfizer Investigational Site — St Louis, Missouri, United States
• Pfizer Investigational Site — Syracuse, New York, United States
• Pfizer Investigational Site — Charlotte, North Carolina, United States
• Pfizer Investigational Site — Minot, North Dakota, United States
• Pfizer Investigational Site — Cincinnati, Ohio, United States
• Pfizer Investigational Site — Mayfield Village, Ohio, United States
• Pfizer Investigational Site — Oklahoma City, Oklahoma, United States
• Pfizer Investigational Site — Danville, Pennsylvania, United States
• Pfizer Investigational Site — State College, Pennsylvania, United States
• Pfizer Investigational Site — Wexford, Pennsylvania, United States
• Pfizer Investigational Site — Birmingham, Alabama, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.